Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Debt (2020 - 2025)

Candel Therapeutics' Total Debt history spans 4 years, with the latest figure at $20.5 million for Q4 2023.

  • On a quarterly basis, Total Debt rose 1.6% to $20.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $20.5 million, a 1.6% increase, with the full-year FY2023 number at $20.5 million, up 1.6% from a year prior.
  • Total Debt hit $20.5 million in Q4 2023 for Candel Therapeutics, roughly flat from $20.4 million in the prior quarter.
  • Over the last five years, Total Debt for CADL hit a ceiling of $20.5 million in Q4 2023 and a floor of $463000.0 in Q4 2020.
  • Historically, Total Debt has averaged $12.4 million across 4 years, with a median of $20.2 million in 2022.
  • Biggest five-year swings in Total Debt: surged 3507.5% in 2022 and later increased 1.58% in 2023.
  • Tracing CADL's Total Debt over 4 years: stood at $463000.0 in 2020, then rose by 20.95% to $560000.0 in 2021, then surged by 3507.5% to $20.2 million in 2022, then grew by 1.6% to $20.5 million in 2023.
  • Business Quant data shows Total Debt for CADL at $20.5 million in Q4 2023, $20.4 million in Q3 2023, and $20.4 million in Q2 2023.